Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
The Phase 2b clinical study was designed as an exploratory, multi-center, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with FSAD. Topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm.Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
2b期研究表明，3.6%局部用西地那非乳膏可改善女性性唤起障碍（FSAD）的疗效，特别是在一部分带有或不带有同时存在降低性欲的FSAD女性中表现更佳。
There are currently no FDA-approved therapies for FSAD
目前尚无FDA批准的FSAD治疗方法。
SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG), of the Phase 2b study efficacy results of topical Sildenafil Cream 3.6% (Sildenafil Cream), which is being developed for the treatment of female sexual arousal disorder (FSAD).
2024年6月24日圣地亚哥，全球新闻通讯社（GLOBE NEWSWIRE）——Dare生物科技公司（NASDAQ:DARE）是女性健康和幸福的创新领袖，今天宣布在《产科和妇产学》（Obstetrics & Gynecology)上发表了局部用3.6%西地那非乳膏（西地那非乳膏）2b期研究疗效结果。该药正在开发用于治疗女性性唤起障碍（FSAD）的疗法。《产科和妇产学》该2b期临床研究是一项探索性、多中心、双盲、安慰剂对照研究，旨在评估3.6%局部用西地那非乳膏在绝经前FSAD患者中的初步疗效和安全性。局部用西地那非乳膏改善了FSAD女性的疗效，尤其是在一部分患有或不患有同时降低性欲的女性中疗效最显著的一项探索性后续分析表明，局部用西地那非乳膏显著提高了性唤起感觉，并减轻了性困扰，改善了性欲和性高潮。
The Phase 2b clinical study was designed as an exploratory, multi-center, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with FSAD. Topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm.
该2b期临床研究是一项探索性、多中心、双盲、安慰剂对照研究，旨在评估3.6%局部用西地那非乳膏在绝经前FSAD患者中的初步疗效和安全性。局部用西地那非乳膏改善了FSAD女性的疗效，尤其是在一部分患有或不患有同时降低性欲的女性中疗效最显著的一项探索性后续分析表明，局部用西地那非乳膏显著提高了性唤起感觉，并减轻了性困扰，改善了性欲和性高潮。